177 related articles for article (PubMed ID: 34294370)
21. Implications for eicosapentaenoic acid- and docosahexaenoic acid-derived resolvins as therapeutics for arthritis.
Souza PR; Norling LV
Eur J Pharmacol; 2016 Aug; 785():165-173. PubMed ID: 26165764
[TBL] [Abstract][Full Text] [Related]
22. Ketamine: A tale of two enantiomers.
Jelen LA; Young AH; Stone JM
J Psychopharmacol; 2021 Feb; 35(2):109-123. PubMed ID: 33155503
[TBL] [Abstract][Full Text] [Related]
23. A hypothesis of monoamine (5-HT) - Glutamate/GABA long neural circuit: Aiming for fast-onset antidepressant discovery.
Li YF
Pharmacol Ther; 2020 Apr; 208():107494. PubMed ID: 31991195
[TBL] [Abstract][Full Text] [Related]
24. Eicosapentaenoic and docosahexaenoic acids have different effects on peripheral phospholipase A2 gene expressions in acute depressed patients.
Su KP; Yang HT; Chang JP; Shih YH; Guu TW; Kumaran SS; Gałecki P; Walczewska A; Pariante CM
Prog Neuropsychopharmacol Biol Psychiatry; 2018 Jan; 80(Pt C):227-233. PubMed ID: 28648567
[TBL] [Abstract][Full Text] [Related]
25. Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites.
Yang C; Yang J; Luo A; Hashimoto K
Transl Psychiatry; 2019 Nov; 9(1):280. PubMed ID: 31699965
[TBL] [Abstract][Full Text] [Related]
26. Rapid-acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective.
Hashimoto K
Psychiatry Clin Neurosci; 2019 Oct; 73(10):613-627. PubMed ID: 31215725
[TBL] [Abstract][Full Text] [Related]
27. Arketamine, a new rapid-acting antidepressant: A historical review and future directions.
Zhang JC; Yao W; Hashimoto K
Neuropharmacology; 2022 Nov; 218():109219. PubMed ID: 35977629
[TBL] [Abstract][Full Text] [Related]
28. Antidepressant actions of ketamine engage cell-specific translation via eIF4E.
Aguilar-Valles A; De Gregorio D; Matta-Camacho E; Eslamizade MJ; Khlaifia A; Skaleka A; Lopez-Canul M; Torres-Berrio A; Bermudez S; Rurak GM; Simard S; Salmaso N; Gobbi G; Lacaille JC; Sonenberg N
Nature; 2021 Feb; 590(7845):315-319. PubMed ID: 33328636
[TBL] [Abstract][Full Text] [Related]
29. Intrathecal administration of Resolvin D1 and E1 decreases hyperalgesia in mice with bone cancer pain: Involvement of endocannabinoid signaling.
Khasabova IA; Golovko MY; Golovko SA; Simone DA; Khasabov SG
Prostaglandins Other Lipid Mediat; 2020 Dec; 151():106479. PubMed ID: 32745525
[TBL] [Abstract][Full Text] [Related]
30. Meta-analysis and meta-regression of omega-3 polyunsaturated fatty acid supplementation for major depressive disorder.
Mocking RJ; Harmsen I; Assies J; Koeter MW; Ruhé HG; Schene AH
Transl Psychiatry; 2016 Mar; 6(3):e756. PubMed ID: 26978738
[TBL] [Abstract][Full Text] [Related]
31. International Society for Nutritional Psychiatry Research Practice Guidelines for Omega-3 Fatty Acids in the Treatment of Major Depressive Disorder.
Guu TW; Mischoulon D; Sarris J; Hibbeln J; McNamara RK; Hamazaki K; Freeman MP; Maes M; Matsuoka YJ; Belmaker RH; Jacka F; Pariante C; Berk M; Marx W; Su KP
Psychother Psychosom; 2019; 88(5):263-273. PubMed ID: 31480057
[TBL] [Abstract][Full Text] [Related]
32. Do the dissociative side effects of ketamine mediate its antidepressant effects?
Luckenbaugh DA; Niciu MJ; Ionescu DF; Nolan NM; Richards EM; Brutsche NE; Guevara S; Zarate CA
J Affect Disord; 2014 Apr; 159():56-61. PubMed ID: 24679390
[TBL] [Abstract][Full Text] [Related]
33. Effects of prenatal n-3 fatty acid supplementation on offspring resolvins at birth and 12 years of age: a double-blind, randomised controlled clinical trial.
See VHL; Mas E; Prescott SL; Beilin LJ; Burrows S; Barden AE; Huang RC; Mori TA
Br J Nutr; 2017 Dec; 118(11):971-980. PubMed ID: 29173199
[TBL] [Abstract][Full Text] [Related]
34. Antidepressant-like effects of tomatidine and tomatine, steroidal alkaloids from unripe tomatoes, via activation of mTORC1 in the medial prefrontal cortex in lipopolysaccharide-induced depression model mice.
Deyama S; Sugie R; Tabata M; Kaneda K
Nutr Neurosci; 2023 Sep; ():1-14. PubMed ID: 37704369
[No Abstract] [Full Text] [Related]
35. The role of mTOR in depression and antidepressant responses.
Abelaira HM; Réus GZ; Neotti MV; Quevedo J
Life Sci; 2014 Apr; 101(1-2):10-4. PubMed ID: 24582593
[TBL] [Abstract][Full Text] [Related]
36. GSK-3 inhibition potentiates the synaptogenic and antidepressant-like effects of subthreshold doses of ketamine.
Liu RJ; Fuchikami M; Dwyer JM; Lepack AE; Duman RS; Aghajanian GK
Neuropsychopharmacology; 2013 Oct; 38(11):2268-77. PubMed ID: 23680942
[TBL] [Abstract][Full Text] [Related]
37. Resolvins as proresolving inflammatory mediators in cardiovascular disease.
Capó X; Martorell M; Busquets-Cortés C; Tejada S; Tur JA; Pons A; Sureda A
Eur J Med Chem; 2018 Jun; 153():123-130. PubMed ID: 28732558
[TBL] [Abstract][Full Text] [Related]
38. Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their aspirin-triggered endogenous epimers: an overview of their protective roles in catabasis.
Serhan CN; Gotlinger K; Hong S; Arita M
Prostaglandins Other Lipid Mediat; 2004 Apr; 73(3-4):155-72. PubMed ID: 15290791
[TBL] [Abstract][Full Text] [Related]
39. Ketamine and its metabolites: Potential as novel treatments for depression.
Zhang K; Yao Y; Hashimoto K
Neuropharmacology; 2023 Jan; 222():109305. PubMed ID: 36354092
[TBL] [Abstract][Full Text] [Related]
40. Synaptic mechanisms underlying rapid antidepressant action of ketamine.
Kavalali ET; Monteggia LM
Am J Psychiatry; 2012 Nov; 169(11):1150-6. PubMed ID: 23534055
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
